The National Medical Products Administration plans to strictly regulate live-stream marketing of medical devices and solicits opinions on 4 oral industry standards. Dental Doctor, Aidite, Zhenghai Bi…

China's NMPA: Plans to Strictly Regulate Live-stream Marketing of Medical Devices, Class III Devices May Be Banned from Broadcasting

China's National Medical Products Administration (NMPA) recently publicly solicited opinions on the "Draft Measures for the Supervision and Administration of Online Medical Device Sales," proposing to prohibit the live-stream marketing of Class III medical devices, as well as Class II and Class I medical devices marked for hospital use only. Sales records of operators and records involving implantable medical devices on platforms must be permanently preserved, while other display, transaction, and complaint records on platforms must be retained for no less than five years from the date of transaction completion. The draft stipulates that live-stream marketers must be enterprise employees, continuously display registration certificates or filing numbers, and include warning labels. Earlier in 2025, the "Quality Management Standards for Online Sales of Medical Devices" had been deployed to establish a fully traceable regulatory system across the entire process.

NMPA Solicits Opinions on Four Dental Industry Standards, Covering Degradation Evaluation, Bone Filling, and Water-Based Cements

On August 24, 2026, the NMPA released four draft dental medical device industry standards for public comment, covering in vivo degradation evaluation, osteogenic performance, water-based cements, and oral bone filling materials. The feedback deadline is October 23, 2026. Among the four standards, the water-based cement standard includes a 24-month transition period, while the other three have a 12-month period. Companies need to plan their product line technical upgrades and registration change timelines accordingly.

Dental Doctor 2026H1: Revenue RMB 940 Million, Up 16.93% YoY; Orthodontic Service Revenue Up 24.07% YoY

On August 26, 2026, Dental Doctor Medical Holding Group released its 2026 interim report, with operating revenue of RMB 940 million, a year-on-year increase of 16.93%; net profit attributable to shareholders of the parent company was RMB 90.9039 million, up 37.15%; orthodontic service revenue was RMB 147 million, up 24.07%. The company has deployed 49 directly-operated institutions in East China, plans to add new investments of no more than RMB 200 million, and submitted IPO guidance filing to the Shanghai Stock Exchange in May 2026.

Aidite 2026H1: Revenue RMB 582 Million, Up Approximately 20% YoY; Dental Digital Equipment Revenue Up Over 40%

On August 25, 2026, Aidite (Qinhuangdao) Technology Co., Ltd. released its 2026 interim report, achieving operating revenue of RMB 582 million, a year-on-year increase of 19.75%; dental digital equipment revenue was RMB 136 million, up 41.81%; R&D investment was RMB 43.6985 million, an increase of 54.66%; overseas revenue was RMB 430 million, accounting for 73.85% of total revenue. During the reporting period, the company did not distribute cash dividends, nor did it issue bonus shares or convert capital reserve into share capital.

WHOLE SHINE MEDICAL 2026H1: Dental Medical Service Business Revenue Nearly RMB 300 Million, Up 2.43% YoY; Delun Dental Turned Profitable

On August 26, 2026, WHOLE SHINE MEDICAL released its interim report, with dental medical service revenue of RMB 296 million, a year-on-year increase of 2.43%, accounting for 94.09%; net loss attributable to shareholders of the parent company was RMB 14.0259 million, narrowing by 40.95% year-on-year; subsidiary Delun Medical achieved a net profit of RMB 18.0438 million, turning from loss to profit, with 28 chain clinics and over 500 dental chairs, covering four cities: Guangzhou, Foshan, Zhaoqing, and Huizhou. The report stated that the 6.68% equity stake in Fushun Bank will be judicially auctioned from August 24 to 27, 2026, and if completed, will lead to a corresponding reduction in long-term equity investment.

Zhenghai Bio-Tech 2026H1: Revenue RMB 160 Million, Down 15% YoY; Dental Barrier Membrane Revenue Down 25% YoY

On August 25, 2026, Zhenghai Bio-Tech released its 2026 interim report, achieving operating revenue of RMB 160 million, a year-on-year decrease of 14.94%; net profit attributable to shareholders of the parent company was RMB 33.3061 million, down 27.85% year-on-year. Core product dental barrier membrane revenue was RMB 57.7757 million, down 25.08% year-on-year, with gross margin falling to 78.93%. The company is advancing the volume ramp-up of new products such as active biological bone and calcium-silicon bioceramics, while also laying out new fields including stem cells and injectable fillers.

Shining 3D 2026H1: Revenue RMB 998 Million, Up 45.04% YoY; 3D Scanner Revenue Up Approximately 50% YoY

On August 25, 2026, Shining 3D released its 2026 interim report, with operating revenue of RMB 998 million, a year-on-year increase of 45.04%; net profit attributable to shareholders of the parent company was RMB 284 million, up 60.62%; 3D scanner revenue was RMB 873 million, up 49.16%, with a gross margin of 78.81%; overseas revenue accounted for 79.85% of total revenue. Net cash flow from operating activities was RMB 176 million, up 15.21% year-on-year.

Meyer 2026H1: Medical Equipment Business Revenue RMB 194 Million, Down 5.12% YoY

On August 26, 2026, Meyer released its 2026 interim report, with cumulative operating revenue of RMB 1.066 billion, a year-on-year increase of 4.20%; medical equipment business revenue was RMB 194 million, down 5.12% year-on-year, but medical equipment export revenue was RMB 31 million, up over 100% year-on-year. During the reporting period, net operating cash flow was RMB 267 million, down 32.07% year-on-year. As of the end of the reporting period, the company had cumulatively received RMB 24.0985 million in compensation from defendants including Hefei Dengtefei Medical Equipment Co., Ltd. through court enforcement.

Perfect 2026H1: Revenue RMB 876 Million, Up 22.20%; Toothbrush Product Gross Margin 24.55%

On August 25, 2026, Perfect Group disclosed its 2026 interim report, with operating revenue of RMB 876 million, a year-on-year increase of 22.20%; net profit attributable to shareholders of the listed company was RMB 48.1136 million, up 10.55%. Toothbrush product revenue was RMB 269 million, with a gross margin of 24.55%; overseas market revenue was RMB 512 million, accounting for 58.82% of main business revenue. Net cash flow from operating activities was RMB 50.0959 million, down 37.15% year-on-year. The board of directors approved a cash dividend of RMB 0.18 per share (tax inclusive), totaling RMB 18.1112 million.

Lepu Medical 2026H1: Revenue RMB 3.214 Billion, Down 4.61% YoY; Net Profit Attributable to Shareholders Down 27.71% YoY

On August 22, 2026, Lepu Medical released its 2026 interim report, with operating revenue of RMB 3.214 billion, a year-on-year decrease of 4.61%; net profit attributable to shareholders of the parent company was RMB 499 million, down 27.71% year-on-year; financial expenses were RMB 172 million, up 177% year-on-year. International business revenue was RMB 598 million, up 14.45% year-on-year, accounting for approximately 18.62% of total revenue. As of the end of the reporting period, the medical device segment had cumulatively applied for 2,411 patents, with over 600 products on the market, 709 registration certificates approved by NMPA, 35 FDA certifications, and 196 CE certifications.

Jiahong Dental 2026H1: Revenue RMB 272 Million, Up 5.68% YoY; Overseas Revenue Accounts for Nearly 60%

On August 26, 2026, Jiahong Dental released its 2026 interim report, with operating revenue of RMB 272 million, a year-on-year increase of 5.68%; overseas main business revenue was RMB 160 million, accounting for approximately 59.6%, up 15.02% year-on-year. Net cash flow from operating activities was RMB 43.3188 million, an increase of 212.92% compared to the same period last year. Net profit was RMB 26.7777 million, down 8.54% year-on-year. As of June 30, the company's total assets were RMB 675 million, with book value per share attributable to the parent company of RMB 7.57.

Lantian Dental 2026H1: Dental Medical Service Revenue RMB 200 Million, Up 33.80% YoY

On August 25, 2026, Lantian Dental announced its 2026 interim report, with total operating revenue of RMB 201 million, a year-on-year increase of 31.98%, and net profit attributable to shareholders of the parent company of RMB 5.3769 million, up 17.87%. Among this, revenue from the Anhui region was RMB 51.3272 million, up 433.87%, with its share rising to 25.53%. As of the end of the reporting period, the company's total assets were RMB 472 million, liabilities were RMB 241 million, and the debt-to-asset ratio was 51.13%. Wholly-owned subsidiaries Guigang Hospital and Liuzhou Clinic used 24 commercial units as collateral to apply for a working capital loan of RMB 13 million for daily operational turnover.

Keen Dental Hospital 2026H1: Revenue RMB 152 Million; Intraoral Periodontal Project Revenue Up 47.04% YoY

In the first half of 2026, Dezhou Keen Dental Hospital achieved operating revenue of RMB 152 million, with a net profit of RMB 3.6376 million, a surge of 5094.43% year-on-year; material and equipment gross margin rose to 60.72%, up 42.53 percentage points year-on-year; intraoral periodontal project revenue increased 47.04% to RMB 29.9469 million, with per capita efficiency of approximately RMB 176,500/person, and net operating cash flow reaching RMB 43.001 million. This acquisition formed goodwill of RMB 39.681 million, bringing total goodwill to RMB 118 million.

Huachi Dental 2026H1: Revenue RMB 87.86 Million, Down 6.32%; Orthodontic Service Gross Margin Up 9.13% YoY

On August 25, 2026, Shanghai Huachi Dental Hospital Investment Management Co., Ltd. released its 2026 interim report, with operating revenue of RMB 87.8609 million, a year-on-year decrease of 6.32%; net profit attributable to shareholders of the listed company was RMB 3.9842 million, up 2176.70% year-on-year. The gross margin of the orthodontic business increased by 9.13 percentage points year-on-year. The company disclosed net cash flow from operating activities of RMB 15.8366 million, down 9.48% year-on-year; selling expenses were RMB 11.5612 million, down 21.54% year-on-year; the debt-to-asset ratio was 79.92%, up 1.98 percentage points from the end of the previous year.

Kontour Medical 2026H1: Net Profit Attributable to Shareholders Down 24.74% YoY; R&D Investment Up 74% Putting Pressure on Profits

On August 28, 2026, Kontour(Xi'an) Medical Technology Co., Ltd. released its 2026 interim report, with operating revenue of RMB 171 million during the reporting period; the PEEK material series achieved revenue of RMB 113 million, accounting for 66.21%; net profit attributable to shareholders of the listed company was RMB 41.3937 million, down 24.74% year-on-year; R&D investment was RMB 18.5633 million, accounting for 11.60% of operating revenue, up 74% year-on-year; overseas sales revenue was RMB 17.4986 million, with 5 new overseas registration certificates obtained. The company plans to accelerate the iteration and commercial implementation of differentiated new products such as additively manufactured dental implants and accessory components.

Double Medical 2026H1: Dental Business Revenue Approximately RMB 40.24 Million, Up 14.90% YoY

On August 27, 2026, Double Medical released its 2026 interim report, with net profit attributable to shareholders of the listed company reaching RMB 353 million, up 44.65% year-on-year; operating revenue was RMB 1.34 billion, up 10.69% year-on-year. Among this, sports medicine revenue grew 72.50%, and dental business revenue was RMB 40.2362 million, up 14.90% year-on-year, accounting for approximately 3% of total revenue. During the period, the company repurchased approximately 4.493 million shares through centralized bidding, with a repurchase amount of approximately RMB 185 million.

IMD 2026H1: Net Profit Attributable to Shareholders Turned from Loss to Profit, Gross Margin Rose to 50.35%

In the first half of 2026, Innovative Material and Devices Co., Ltd. achieved operating revenue of RMB 33.867 million, a year-on-year increase of 24.35%; net profit attributable to shareholders of the parent company was RMB 2.281 million, up 169.32%, turning from loss to profit, with gross margin rising to 50.35%. The performance improvement was mainly driven by significant growth in overseas sales and effective cost and expense control. The company's per capita efficiency in the first half of 2026 was approximately RMB 217,100/person.

China Oral Industry Group 2026H1: Revenue RMB 74.247 Million; Dental Clinic Business Revenue Down 7.37% YoY

On August 25, 2026, China Oral Industry Group Holdings Limited released its interim results for the period ending June, with revenue of RMB 74.247 million, a year-on-year decrease of 32.05%, and a loss of approximately RMB 10.986 million. The loss was mainly attributed to the gross margin of inflatable products turning negative to -2.5% and a sharp 94.32% decline in North American revenue. During the same period, mainland China revenue was RMB 47.067 million, up 49.6% year-on-year, accounting for 63.4% of total revenue. As of June 30, the company's total assets were RMB 164 million, cash was RMB 16.549 million, and the debt-to-asset ratio rose to 10.2%.

Huamei Dental 2026H1: Revenue RMB 50.23 Million, Up 4.35% YoY; Net Profit Attributable to Shareholders Down 16.41% YoY

On August 24, 2026, Huamei Dental released its interim report, with operating revenue of RMB 50.2305 million, a year-on-year increase of 4.35%; net profit attributable to shareholders of the parent company was RMB 3.937 million, down 16.41% year-on-year; non-GAAP net profit was RMB 3.5585 million, up 43.73% year-on-year. Due to the closure of a Chengdu clinic and the accrual of RMB 2.1887 million in litigation expenses, selling expenses of RMB 2.8422 million decreased by 25.63%. The company acquired a 51% equity stake in Chengdu Gaoxin Yiya Dental Clinic for RMB 360,000, involving a trademark lawsuit of RMB 10.1 million. The company currently operates under a DSO model, with profitability primarily derived from store medical services.

135,000 People Affected by Data Breach, US Dental Institution Reaches Class Action Settlement

On August 24, 2026, a Minnesota community dental care institution reached a class action settlement over a data breach affecting approximately 135,000 patients. Affected individuals can apply for compensation before October 19, 2026, with up to USD 5,000 or a base amount of USD 50, plus two years of medical and credit monitoring services. The institution operates 5 clinics across the state, involving 134,903 patients. The final hearing is scheduled for November 23, 2026.

Q & M Dental Group Plans to Sell 60% Equity in AI Dental Technology Subsidiary for RMB 35.76 Million

On August 14, 2026, Q & M Dental Group (Singapore) Limited signed a non-binding Memorandum of Understanding with Medi Lifestyle Limited, deciding to sell a 60% equity stake in its wholly-owned subsidiary EM2AI for approximately SGD 6.76 million (approximately RMB 35.76 million). The transaction consideration is the issuance of 138,000,000 ordinary shares at SGD 0.049 per share. Upon completion of the transaction, Q & M Dental Group will retain a 40% equity stake. The buyer has committed to raising no less than SGD 30 million within two years for business expansion in Singapore and Southeast Asia.

Dental Materials Company Graphy Plans to Acquire 26.14% Equity in Dental Digital Diagnosis and Treatment Equipment Manufacturer Ray for RMB 240 Million

On August 10, 2026, South Korean dental materials company Graphy Inc. acquired a 26.14% equity stake in Ray Co., Ltd. for approximately KRW 49.2 billion (approximately RMB 241 million), becoming the largest shareholder. The acquisition involves 4,087,749 shares, completed in two phases on September 15 and 16. Graphy raised approximately RMB 245 million in acquisition funds through the issuance of convertible bonds and convertible preferred shares, and will nominate directors to Ray's board after the transaction.

Sonendo's First Half 2026 Loss Improved by Approximately 60%, Plans Refinancing to Drive Cash Flow Balance

On August 25, 2026, dental technology company Sonendo reported first-half revenue of USD 14.5 million, with an Adjusted EBITDA loss of USD 2.8 million, an improvement of approximately 60% compared to the same period in 2025. The company launched the Flex program, enabling the GentleWave system with no upfront equipment costs through a commitment to ongoing consumable purchases. Additionally, the company completed USD 15.5 million in senior secured loans, USD 4.5 million in committed capital, and USD 5 million in subordinated financing, used to refinance USD 13.7 million in existing debt. The company stated that with the market penetration of the Flex program and the stabilization of its capital structure, the positive inflection in its cash flow will have greater sustainability.

UK's Fourth Largest Dental Laboratory Receives Private Equity Investment, Plans to Accelerate Digital Dentistry Expansion

On August 24, 2026, Ethos Partners LLP completed a strategic private equity investment in Labyrinth Dental, a UK full-service dental laboratory group, aimed at accelerating the nationwide rollout of its intraoral digital scanners. Labyrinth operates 8 laboratories, serving over 2,000 NHS and private dentists, with a compound annual growth rate of over 20% in revenue over the past three years. The company plans to deploy scanners free of charge and provide training to help dentists achieve digital workflows. Following the investment, founder and CEO Michael Coldicott and others will remain in their roles, with Zak Smith serving as board chairman and Suddy Bharaj as chief financial officer.

Arcato's Non-Opioid Dental Analgesic Gel Achieves Success in Phase I Clinical Trial and Completes First Round of Fully Subscribed Financing

On August 19, 2026, Arcato Laboratories announced that its non-opioid dental analgesic gel ARC-001 met the primary safety endpoint in a Phase I clinical trial and completed a first round of fully subscribed financing. The single-dose gel contains benzocaine, lidocaine, and bupivacaine, and can be administered locally after tooth extraction, expected to provide up to 7 days of pain relief. Exploratory data showed reduced pain at 24 hours post-surgery, with the placebo group using opioids twice as frequently as the ARC-001 group. The company did not disclose the closing date of this financing round.

Henry Schein's BioHorizons Launches Allograft Growth Factor to Support Oral Hard Tissue Regeneration

In August 2026, dental implant company BioHorizons launched Prolifica™, an allograft growth factor that preserves at least 16 natural proteins and utilizes biphasic release technology to achieve an initial surge of factors followed by sustained slow release. It is suitable for use alone in bone grafting or in combination with autogenous bone and other allografts. CEO Steve Boggan and Senior Director of Biomaterials Jason Cordell both noted that this technology aims to enhance hard tissue regeneration outcomes. As of press time, the company has not disclosed the recommended retail price of Prolifica in the Chinese market or the official approval and launch timeline.